Report Snapshot

Shionogi 

• Shionogi’s overall sales of FY2019 declined by 7.9% due to the large decrease in domestic sales of its influenza family drugs such as Xofluza, Rapiacta, and Brightpoc.
• Shionogi compares unfavorably to most peers over near-term (2019–24) and slightly favorably in long-term (2024– 29) revenue growth rates; the company is expected to generate less than 4% of revenue from launch products in 2025, which is much lower than peer average.
• Pharma Intelligence forecasts Shionogi’s revenue to remain flat through to 2029, with royalties from its HIV franchise accounting for the largest single proportion of revenues.
• Cymbalta’s sales are expected to reduce due to poor performance of the drug in first-line chronic lower back pain.
• Shionogi expects to generate a majority of its revenue from the infectious diseases therapeutic area, through global expansion of its HIV franchise.
• To drive its medium- and long-term growth, Shionogi will continue to focus on its home market of Japan and the US, and aim to build up its business in China, which is projected to see the strongest growth in pharmaceutical demand over the next decade.
• Shionogi is developing strategies to overcome the ‘dolutegravir cliff’, when profits from its HIV franchise are expected to decline due to expiration of patents for Tivicay, starting in 2028.
• Symproic is expected to support an efficient business in the US, with a projected CAGR 18.5%.
• Intuniv’s sales are expected to peak till 2022 and will begin to decline due to patent expiration.
• In May 2020, Shionogi and Tetra Therapeutics entered into a definitive merger agreement, under the terms of which, Tetra Therapeutics will become a wholly owned subsidiary of Shionogi, and Shionogi will obtain global rights to Tetra Therapeutics’ entire portfolio of compounds for the treatment of brain disorders associated with cognitive and memory deficits, notably BPN14770, a selective inhibitor of phosphodiesterase‐4D (PDE4D).